Offenbar gibt es noch Sicherheitsprobleme. Klar ist das ein riesiger Zock und nach derzeitiger Info, Abwicklung ist der Cashbestand jetzt im März vielleicht noch 140 Millionen, abzüglich Verbindlichkeiten, sind wir so bei 125 Millionen NAV, wenn man Tesetaxel auf 0 abschreiben möchte. Aber die Vita von Tang liest sich schon recht so, dass er ein schlaues Kerlchen ist, was buttert der noch Millionen im Dezember in die Company, wenn die Ergebnisse von Contessa Phase III massive Zweifel an einer Zulassung lassen. Das passt alles hinten und vorne nicht zusammen. Hier die Vita von Kevin Tang, was der alles schon erfolgreich gemanaged hat:
Kevin Tang
Chairman and Chief Executive Officer
Mr. Tang has served as our Chairman and Chief Executive Officer since the Company’s inception in 2013. He also serves as President of Tang Capital Management, LLC, a life sciences-focused investment company he founded in 2002. Since 2014, Mr. Tang has served as a director and Chairman of La Jolla Pharmaceutical Company. From 2009 to 2020, he served as a director of Heron Therapeutics, Inc. and, from 2012 to 2020, served as Chairman. From 2009 through its acquisition by Endo Pharmaceuticals, Inc. in 2010, Mr. Tang served as a director of Penwest Pharmaceuticals Co. In 2006, he co-founded Ardea Biosciences, Inc. and served as a director from inception through its acquisition by AstraZeneca PLC in 2012. From 2001 to 2008, Mr. Tang served as a director of Trimeris, Inc. From 1993 to 2001, he held various positions at Deutsche Banc Alex Brown, Inc., an investment banking firm, most recently serving as Managing Director and head of the firm’s Life Sciences research group. Mr. Tang received a B.S. degree from Duke University.
|
|
2
Thread abonnieren
